An NF-κB/IRF1 axis programs cDC1s to drive anti-tumor immunity
G. Ghislat, A. S. Cheema, E. Baudoin, C. Verthuy, P. Ballester, K. Crozat, N. Attaf, C. Dong, P. Milpied, B. Malissen, N. Auphan-Anezin, T.-P. V. Manh, M. Dalod, T. Lawrence
Abstract
Conventional type 1 dendritic cells (cDC1s) are critical for anti-tumor immunity. They acquire antigens from dying tumor cells and cross-present them to CD8+ T cells, promoting the expansion of tumor-specific cytotoxic T cells. However, the signaling pathways that govern the anti-tumor functions of cDC1s are poorly understood. We mapped the molecular pathways regulating intra-tumoral cDC1 maturation using single cell RNA sequencing. We identified NF-{kappa}B and IFN pathways as being highly enriched in a subset of functionally mature cDC1s. The specific targeting of NF-{kappa}B or IFN pathways in cDC1s prevented the recruitment and activation of CD8+ T cells and the control of tumor growth. We identified an NF-{kappa}B-dependent IFN{gamma}-regulated gene network in cDC1s, including cytokines and chemokines specialized in the recruitment and activation of cytotoxic T cells. We used single cell transcriptomes to map the trajectory of intra-tumoral cDC1 maturation which revealed the dynamic reprogramming of tumor-infiltrating cDC1s by NF-{kappa}B and IFN signaling pathways. This maturation process was perturbed by specific inactivation of either NF-{kappa}B or IRF1 in cDC1s, resulting in impaired expression of IFN-{gamma}-responsive genes and consequently a failure to efficiently recruit and activate anti-tumoral CD8+ T cells. Finally, we demonstrate the relevance of these findings to cancer patients, showing that activation of the NF-{kappa}B/IRF1 axis in association with cDC1s is linked with improved clinical outcome. The NF-{kappa}B/IRF1 axis in cDC1s may therefore represent an important focal point for the development new diagnostic and therapeutic approaches to improve cancer immunotherapy. One Sentence SummaryNF-{kappa}B and IRF1 coordinate intra-tumoral cDC1 maturation and control of immunogenic tumor growth.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- cDC1 and interferons promote spontaneous CD4+ and CD8+ T cell protective responses to breast cancer
R. Mattiuz, C. Brousse, … K. Crozat·bioRxiv·Dec 23, 2020
- Interferon-induced lysosomal membrane permeabilization and death cause cDC1-deserts in tumors.
E. Aerakis, A. Chatzigeorgiou, … M. Tsoumakidou·bioRxiv·Mar 14, 2022
- STING Licensing of Type I Dendritic Cells Potentiates Antitumor Immunity
- Intratumoral cDC1-T Cell Clusters Serve as Sites of Local Costimulation to Enhance CTL-Mediated Tumor Rejection
Catherine B. Carbone, Markus K. Brown, … Christine Moussion·bioRxiv·May 19, 2025
- Ripk1 Deficiency or K376R Mutation in Dendritic Cells Promotes Potent Antitumor Immunity
Yangjing Ou, Lingxia Wang, … Haibing Zhang·bioRxiv·Feb 6, 2026
- Nuanced role for dendritic cell intrinsic IRE1 RNase in the regulation of antitumor adaptive immunity.
F. Flores-Santibanez, S. Rennen, … F. Osorio·bioRxiv·Jul 20, 2022